By 2025, ZS predicts that roughly 100,000 patients will be eligible to receive one of the 34 approved CAR-T cell therapies expected to be on the market. However, our research, which is based on discussions with patients, manufacturers, providers and key opinion leaders (KOLs), suggests that biopharma companies could fall well short of that estimate if they fail to clear the numerous hurdles to achieving scale. In this presentation, which ZS delivered at the 2021 CAR-TCR Summit, we offer our predictions about what the cell therapy landscape will look like in 2025 based on the voices of industry stakeholders and our own extensive research.
Key takeaways:
- Hear how CAR-T therapies risk going the way of the Concorde jet if the markets start to choose efficiency and convenience over innovation between now and 2025.
- Gain a better understanding about why allogeneic therapies may not be the silver bullet to expanding access to CAR-T therapies in the community setting.
- Learn how Tesla’s efforts to build a nationwide charging network by releasing its intellectual property around battery design could be a model for how CAR-T manufacturers can overcome rate limiters together.
Add insights to your inbox
We’ll send you content you’ll want to read – and put to use.
